- Home
- ROIV vs DCI Comparison
ROIV vs DCI Comparison
Compare ROIV & DCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | DCI |
|---|---|---|
| Founded | 2014 | 1915 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pollution Control Equipment |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 10.5B |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | ROIV | DCI |
|---|---|---|
| Price | $21.33 | $91.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $24.31 | ★ $92.50 |
| AVG Volume (30 Days) | ★ 8.3M | 750.6K |
| Earning Date | 02-09-2026 | 12-04-2025 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.21 |
| Revenue | $20,329,000.00 | ★ $3,726,200,000.00 |
| Revenue This Year | N/A | $4.61 |
| Revenue Next Year | $741.42 | $4.58 |
| P/E Ratio | ★ N/A | $28.05 |
| Revenue Growth | N/A | ★ 2.37 |
| 52 Week Low | $8.73 | $57.45 |
| 52 Week High | $23.47 | $95.00 |
Technical Indicators
Market Signals| Indicator | ROIV | DCI |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 53.38 |
| Support Level | $21.36 | $88.50 |
| Resistance Level | $22.21 | $93.52 |
| Average True Range (ATR) | 0.73 | 1.38 |
| MACD | -0.17 | -0.42 |
| Stochastic Oscillator | 19.30 | 50.40 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.